XML 56 R45.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Fair Value Measurements - Narrative (Details) - USD ($)
Dec. 31, 2019
Dec. 31, 2018
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Current portion of contingent consideration $ 25,600,000 $ 32,300,000
Brabant Pharma Limited    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Potential contingent payment, minimum 0  
Potential contingent payment, maximum 75,000,000.0  
Current portion of contingent consideration 25,600,000  
Business Combination, Contingent Consideration, Liability $ 38,200,000  
Warrants From July 2011 Debt Financing [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Number of common stock that can be purchased (shares) 28,125  
Exercise price of warrants (in usd per share) $ 72.00